Tipranks Press Release.
ADMA Biologics Inc (ADMA) posted 13% sequential revenue growth to $141.1 million with gross margin jumping to 71%, prompting an increase in full-year 2026 adjusted EBITDA and net income guidance.
According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.
Recent performance swings in ADMA Biologics (ADMA) have put fresh attention on what investors are paying for its plasma-derived therapies business after a year of sharp declines and a much stronger past 3 months. The recent rebound in ADMA Biologics, with a 12.07% 90‑day share price return, contrasts sharply with a year‑to‑date share price decline of 47.54%, while a very large 5‑year total shareholder return of about 7x signals that long‑term holders have seen substantial gains. Scan beyond...
Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.
Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the prior day.
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ADMA Biologics stock is downgraded to Hold as FY26 guidance drops and growth slows. See ADMA's ASCENIV outlook, BIVIGAM decline, and $9.52 DCF.
This is the newest page. Registered accounts read further back.